HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by SCHWARTZ, P. E. Search for Related Content PubMed PubMed Citation Articles by SCHWARTZ, P. E.

Combination Chemotherapy in the Management of Ovarian Germ Cell Malignancies

From the Department of Obstetrics and Gynecology Yale University, School of Medicine, New Haven, Connecticut

Abstract

Twenty-four patients with ovarian germ cell malignancies received combination chemotherapy in the present series. Fifteen patients received intensive vincristine, actinomycin- D, and cyclophosphamide therapy for 12 to 18 courses, and 13 are alive and free of disease 34 to 86 months later. One patient with a stage III pure endodermal sinus tumor and one patient with a stage III mixed germ cell tumor composed predominantly of endodermal sinus tumor elements failed vincristine, actinomycin-D, and cyclophosphamide therapy, but each transiently responded to cis-diamminedichloroplatinum, vinblastine, and bleomycin therapy. Nine patients subsequently were treated on a new protocol that used the intensive vincristine, actinomycin-D, and cyclophosphamide regimen for five to six courses for all stage I ovarian germ cell malignancies and cis-diamminedichloroplatinum, vinblastine, and bleomycin therapy for advanced stage tumors containing endodermal sinus tumor. Each patient on the new protocol is alive and free of disease 14 to 26 months later. Short-term intensive vincristine, actinomycin-D, and cyclophosphamide therapy is recommended for all stage I ovarian germ cell malignancies requiring adjuvant chemotherapy. Preservation of ovarian and reproductive function is appropriate in the present group of patients. Vincristine, actinomycin-D, and cyclophosphamide therapy is also recommended for biomarker negative advanced stage ovarian germ cell malignancies. Cis-diamminedichloroplatinum, vinblastine, and bleomycin therapy is recommended for advanced stage biomarker positive ovarian germ cell malignancies. Serial a-fetoprotein (AFP) titers accurately reflect the status of endodermal sinus tumor elements and may be used as a guide to discontinue treatment for patients with pure endodermal sinus tumor malignancies, obviating the need for second-look surgery.

This article has been cited by other articles:

				D. M. Gershenson, A. M. Miller, V. L. Champion, P. O. Monahan, Q. Zhao, D. Cella, and S. D. Williams Reproductive and Sexual Function After Platinum-Based Chemotherapy in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study J. Clin. Oncol., July 1, 2007; 25(19): 2792 - 2797. [Abstract] [Full Text] [PDF]

				P. C. Rogers, T. A. Olson, J. W. Cullen, D. F. Billmire, N. Marina, F. Rescorla, M. M. Davis, W. B. London, S. J. Lauer, R. H. Giller, et al. Treatment of Children and Adolescents With Stage II Testicular and Stages I and II Ovarian Malignant Germ Cell Tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891 J. Clin. Oncol., September 1, 2004; 22(17): 3563 - 3569. [Abstract] [Full Text] [PDF]

				J. Tangir, D. Zelterman, W. Ma, and P. E. Schwartz Reproductive Function After Conservative Surgery and Chemotherapy for Malignant Germ Cell Tumors of the Ovary Obstet. Gynecol., February 1, 2003; 101(2): 251 - 257. [Abstract] [Full Text] [PDF]

				S.-C. J. Yeung, A. C. Chiu, R. Vassilopoulou-Sellin, and R. F. Gagel The Endocrine Effects of Nonhormonal Antineoplastic Therapy Endocr. Rev., April 1, 1998; 19(2): 144 - 172. [Abstract] [Full Text]